The researchers propose to study the airways of asthmatics given TPI ASM8 for 14 days, and examine the protective effects on allergen-induced bronchoconstriction, hyperresponsiveness and airway inflammation.
Early and late asthmatic responses were attenuated by ASM8 and by placebo solution.Methacholine challenge was not affected by study medication. Other parameters were unchanged.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
18
King's College inLondon
London, London, United Kingdom
Safety and allergen-induced maximum decrease in FEV1 for Late Asthmatic Response
Time frame: Safety (Trial duration) + LAR (Day 14)
Exploratory Endpoints only: EAR on Day 14, AMP-induced airway hyperresponsiveness on Day 10,eNO on Day 14, PK/PD in sputum and plasma
Time frame: study duration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.